MAGNET lithium trial
The MAGNET lithium trial studies the efficacy of lithium carbonate in ALS patients positive for the homozygous UNC13A mutation.
Lithium carbonate
Lithium carbonate has a long history as a treatment for mood disorders. Several studies have highlighted the protective effects of Lithium carbonate in the brain. An analysis of ALS patients treated with Lithium carbonate showed that patients carrying the homozygous UNC13a mutation may respond better than patients who do not carry this gene. The UNC13a gene is known to be associated with the prognosis and symptoms of patients with ALS. Earlier studies have shown that lithium is safe for patients. In this treatment arm we aim to confirm the beneficial effect of Lithium carbonate in patients positive for the homozygous UNC13a mutation.
Participating TRICALS centres
Bellvitge University Hospital
Spain, Barcelona
Monica Povedano Panades
Coordinator of Unit
Karolinska Institute
Sweden, Stockholm
Caroline Ingre
Associate Professor of Neurology
King’s College, London
United Kingdom, London
Ammar Al-Chalabi
Professor of Neurology and Complex Disease Genetics
Queen Square Institute of Neurology
Uni, London
Andrea Malaspina
Professor of Neurology
Royal Stoke University Hospital
United Kingdom, Stoke on Trent
Tom Lambert
Neurologist
UMC Utrecht
The Netherlands, Utrecht
Leonard van den Berg
Professor of Neurology
UZ Leuven
Belgium, Leuven
Philip van Damme
Professor of Neurology
